Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Manhattan Scients

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-18T21:00:00Z
VOLUME
4556332
Market Cap
0.01M

Momentum Score

…

Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Manhattan Scients (MHTX) is an OTC‑Pink quoted microcap that, based on limited public disclosures, appears to be a development‑stage company focused on commercializing intellectual property in technology and life sciences. Long‑term growth may depend on successful commercialization or licensing of IP, strategic partnerships and regulatory approvals that could support revenue, which may appeal to investors seeking early‑stage IP exposure.
Material risks include limited public disclosure, low liquidity and thin trading, likely lack of revenues, high execution and financing risk such as dilution, and potential regulatory or legal exposure.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.05M
Debt / Equity
-0.03
ROE
-1286.89%
Net Debt
-0.01M
ROCE
64.65%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -1.17M -2.73M -3.64M 4.31M -1.22M
Net income -1.17M -4.76M -3.67M 4.31M -1.23M
Selling general administrative 0.69M 0.72M 0.73M 0.71M 1.11M
Selling and marketing expenses 0.00M - - - -
Gross profit -0.00M 0.05M 0.05M 0.05M 0.10M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit -1.17M -0.68M -0.69M -0.68M -1.02M
Ebitda -1.16M -0.68M -0.69M -0.67M -1.02M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M 0.00M
Non operating income net other - - - 5.01M -0.19M
Operating income -0.70M -0.68M -0.69M -0.68M -1.02M
Other operating expenses 0.70M 0.73M 0.74M 0.72M 1.12M
Interest expense 0.00M 0.02M 0.03M 0.03M 0.01M
Tax provision - - - - 0.00M
Net interest income 0.00M -0.02M -0.03M -0.03M -0.01M
Income tax expense -1.17M 2.03M 0.03M 0.03M 0.01M
Total revenue 0.00M 0.05M 0.05M 0.05M 0.10M
Total operating expenses 0.70M 0.73M 0.74M 0.72M 1.12M
Cost of revenue 0.00M - - 0.72M 0.00M
Total other income expense net -0.46M -2.05M -2.95M 4.99M -0.20M
Net income from continuing ops -1.17M -2.73M -3.64M 4.31M -1.22M
Net income applicable to common shares - - -3.64M 4.31M -1.22M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 0.32M 1.03M 3.45M 6.85M 2.23M
Other current assets 0.00M 0.01M 0.32M 0.31M 0.31M
Total liab 2.12M 2.73M 2.42M 2.17M 3.23M
Total stockholder equity -1.80M -1.70M 1.03M 4.67M -1.00M
Other current liab 1.92M 1.44M 1.13M 0.85M 1.86M
Common stock 0.56M 0.56M 0.56M 0.56M 0.56M
Capital stock 0.56M 0.56M 0.56M 0.56M 0.56M
Retained earnings -72.42M -71.25M -68.52M -64.88M -69.19M
Other assets - - 0.00M 0.30M 0.60M
Cash 0.07M 0.17M 0.23M 0.35M 0.26M
Total current liabilities 2.12M 1.67M 1.36M 1.01M 2.09M
Current deferred revenue 0.01M - - - -
Net debt -0.01M -0.07M -0.10M -0.25M -0.18M
Short term debt 0.06M 0.11M 0.13M - -
Short long term debt 0.06M 0.11M 0.13M - -
Short long term debt total 0.06M 0.11M 0.13M 0.10M 0.08M
Other stockholder equity 69.56M 69.00M 69.00M 69.00M 67.63M
Property plant equipment - - 0.00M 0.01M 0.00M
Total current assets 0.07M 0.19M 0.55M 0.67M 0.57M
Long term investments 0.24M 0.84M 2.90M 5.88M 1.04M
Net tangible assets - - 1.03M 4.67M -1.00M
Short term investments - - - 5.88M -
Net receivables - - 0.30M 0.30M 0.30M
Long term debt - - - 0.10M 0.08M
Inventory - - -0.30M -0.30M -0.30M
Accounts payable 0.13M 0.12M 0.10M 0.16M 0.23M
Accumulated other comprehensive income -0.56M - - - -
Common stock total equity - - - 0.56M 0.56M
Preferred stock total equity - - - 1.06M -
Retained earnings total equity - - - -64.88M -69.19M
Non currrent assets other 0.00M 0.00M 0.00M 0.30M 0.60M
Non current assets total 0.25M 0.84M 2.91M 6.18M 1.65M
Long term debt total - - - - 0.08M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.10M 0.33M 0.30M 0.18M 0.04M
Change to liabilities - - 0.17M -0.01M 0.34M
Total cashflows from investing activities 0.10M - 0.30M 0.48M 0.34M
Net borrowings -0.02M - - - 0.15M
Total cash from financing activities -0.02M -0.04M - 0.02M 0.15M
Change to operating activities - - -0.00M 0.27M -0.00M
Net income -1.17M -2.73M -3.64M 4.31M -1.22M
Change in cash -0.11M -0.06M -0.12M 0.09M 0.17M
Begin period cash flow 0.17M 0.23M 0.35M 0.26M 0.09M
End period cash flow 0.07M 0.17M 0.23M 0.35M 0.26M
Total cash from operating activities -0.19M -0.35M -0.42M -0.39M -0.32M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Other cashflows from investing activities - - - 0.30M 0.30M
Other cashflows from financing activities -0.02M 0.33M 0.30M -0.02M -0.21M
Change to netincome - - 3.02M 0.02M 0.19M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating - - - -4.74M 0.36M
Cash and cash equivalents changes - - - 0.09M 0.17M
Change in working capital 0.51M 0.33M 0.17M 0.26M 0.34M
Other non cash items 0.46M 2.05M 3.05M -4.96M 0.56M
Free cash flow -0.19M -0.35M -0.42M -0.39M -0.32M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MHTX
Manhattan Scients
-
-%
0.00 - - 78.30 15.64 281.64 -1.61
ABT
Abbott Laboratories
-0.10
0.10%
103.87 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-
-%
100.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-0.13
0.04%
313.08 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
0.64
1.35%
48.14 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Manhattan Scients

Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.

244 Fifth Avenue, New York, NY, United States, 10001

212 541 2405

Name Title Year Born
Mr. Marvin Maslow Founder & Chairman 1938
Mr. Emmanuel Tsoupanarias Pres, CEO & Director 1953
Mr. Leonard C. Friedman Sec. 1938
Mr. Robert Romeo Proulx Pres of Imagion 1958
Mr. Marvin Maslow Founder & Chairman of the Board 1938
Mr. Emmanuel Tsoupanarias President, CEO & Director 1953
Mr. Leonard C. Friedman Secretary 1938
Mr. Robert Romeo Proulx President of Imagion 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…